Scarica l'app Stockscreener
213.47
0.85%
-1.84
Dopo l'orario di chiusura:
215.30
1.83
+0.86%
Precedente Chiudi:
$215.31
Aprire:
$215.86
Volume 24 ore:
1.12M
Relative Volume:
0.79
Capitalizzazione di mercato:
$30.57B
Reddito:
$2.50B
Utile/perdita netta:
$-226.32M
Rapporto P/E:
-130.07
EPS:
-1.6412
Flusso di cassa netto:
$71.51M
1 W Prestazione:
-2.44%
1M Prestazione:
+9.90%
6M Prestazione:
-10.73%
1 anno Prestazione:
+30.36%
Intervallo 1D:
$212.03
$220.09
Intervallo di 1 settimana:
$204.16
$227.90
Portata 52W:
$131.81
$256.36
Natera Inc Stock (NTRA) Company Profile
Nome
Natera Inc
Settore
Industria
Telefono
650-249-9090
Indirizzo
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
213.47 | 30.84B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
469.63 | 175.70B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
183.53 | 130.44B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
561.17 | 44.34B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
132.69 | 38.25B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
363.34 | 35.87B | 3.77B | 449.25M | 240.68M | 7.8556 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-14 | Iniziato | William Blair | Outperform |
| 2026-01-07 | Iniziato | Citigroup | Buy |
| 2025-12-02 | Ripresa | Morgan Stanley | Overweight |
| 2025-10-27 | Aggiornamento | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | Ripresa | Wells Fargo | Equal Weight |
| 2025-03-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-08 | Ripresa | Craig Hallum | Buy |
| 2024-02-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | Reiterato | BTIG Research | Buy |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-11-13 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | Iniziato | Bernstein | Mkt Perform |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-05 | Iniziato | UBS | Buy |
| 2023-01-18 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-04-25 | Iniziato | Stephens | Overweight |
| 2022-03-08 | Iniziato | Goldman | Buy |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-05-25 | Iniziato | Wells Fargo | Overweight |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-10-08 | Iniziato | BTIG Research | Buy |
| 2020-09-28 | Iniziato | Morgan Stanley | Overweight |
| 2020-09-17 | Iniziato | SVB Leerink | Outperform |
| 2020-06-10 | Ripresa | Piper Sandler | Overweight |
| 2020-05-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-10-05 | Iniziato | JP Morgan | Neutral |
| 2018-07-05 | Reiterato | Piper Jaffray | Overweight |
| 2017-08-07 | Reiterato | Morgan Stanley | Overweight |
| 2016-11-10 | Reiterato | The Benchmark Company | Buy |
| 2016-05-23 | Reiterato | The Benchmark Company | Buy |
| 2016-05-11 | Reiterato | The Benchmark Company | Buy |
| 2016-04-19 | Iniziato | The Benchmark Company | Buy |
| 2015-09-28 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2015-08-14 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | Iniziato | Robert W. Baird | Outperform |
| 2015-07-27 | Iniziato | Morgan Stanley | Equal-Weight |
| 2015-07-27 | Iniziato | Piper Jaffray | Overweight |
| 2015-07-27 | Iniziato | Wedbush | Neutral |
Mostra tutto
Natera Inc Borsa (NTRA) Ultime notizie
Natera Pushes MRD And Panorama Into Treatment Guiding Roles - Yahoo Finance
Billionaire Stanley Druckenmiller Likes This Cancer Stock - Insider Monkey
How Investors May Respond To Natera (NTRA) Expanding Signatera MRD Reach Amid Insider Share Sale - simplywall.st
NTRA & Diakonos partner to use Signatera in refractory melanoma trial - MSN
This Insider Has Just Sold Shares In Natera - Moomoo
Natera to launch enhanced Panorama NIPT for low fetal fractions - MSN
Net income of Natera, Inc. – XETR:45E - TradingView
Assessing Natera (NTRA) Valuation After Strong Multi Year Returns And Recent Share Price Cooling - simplywall.st
5 Healthcare Stocks That the AI Crowd Is Overlooking - Barron's
Natera, Inc. Balance Sheet – XETR:45E - TradingView
Goldman Sachs Initiates Natera(NTRA.US) With Hold Rating, Announces Target Price $245 - Moomoo
Natera's EXPAND trial enrollment crosses 2,000 patient milestone - MSN
Insider Sell Alert: Steven Chapman Sells 41,124 Shares of Natera Inc (NTRA) - GuruFocus
Natera CEO Steven Chapman sells $9.09 million in company stock By Investing.com - Investing.com South Africa
Natera CEO Steven Chapman sells $9.09 million in company stock - Investing.com UK
Natera(NTRA.US) Officer Sells US$9.09 Million in Common Stock - Moomoo
Natera (NTRA) CEO Chapman sells 41,124 shares under 10b5-1 plan - Stock Titan
(NTRA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
[144] Natera, Inc. SEC Filing - Stock Titan
Natera Expands Board, Appoints Thomas Lynch as Director - TipRanks
Natera (NTRA) appoints independent director Thomas Lynch and expands board - Stock Titan
Natera executive chairman sells $1.64m in shares - Investing.com
NTRA Initiates Coverage On Goldman Sachs -- Rating Set to Neutra - GuruFocus
Natera, Inc. Earnings and Revenue – XETR:45E - TradingView
Goldman Sachs initiates Natera stock with Neutral rating, $245 target - Investing.com UK
Goldman Sachs initiates Natera stock with Neutral rating, $245 target By Investing.com - Investing.com South Africa
Natera CytoDyn Signatera Pact Highlights Data Assets And Rich Valuation - simplywall.st
Natera partners with CytoDyn on cancer treatment research By Investing.com - Investing.com South Africa
Steven L. Chapman reports common‑share sales (NASDAQ: NTRA) - Stock Titan
CytoDyn (CYDY) Teams Up with Natera for Cancer Research Collaboration - GuruFocus
Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer - CytoDyn Inc.
Natera Inc stock (US6323071042): insider sales and new oncology board appointments in focus - AD HOC NEWS
Natera expands Austin operations with new sequencing facility - MSN
Natera, CytoDyn Partner in Colorectal Cancer Study - Contract Pharma
Natera partners with CytoDyn on cancer treatment research - Investing.com
DNA blood test to track tumors in new colon cancer drug trial - Stock Titan
Natera adds two oncology experts to board of directors - Investing.com UK
Insider Sell Alert: Solomon Moshkevich Sells 3,000 Shares of Nat - GuruFocus
Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors - BioSpace
Natera president sells $655,294 of common stock - Investing.com
Natera (NTRA) clinical diagnostics president sells 3,000 shares under 10b5-1 plan - Stock Titan
Natera president sells $655,294 of common stock By Investing.com - Investing.com Canada
Natera(NTRA.US) Director Sells US$17.18 Million in Common Stock - Moomoo
Director Roelof Botha-linked vehicles sell 78K Natera (NTRA) shares - Stock Titan
Natera Adds Oncology Veterans Thomas Lynch and Eric Rubin to Board - citybiz
IVF Patients Say Natera Profited Off Ineffective Embryo Tests - Law360
Natera adds two oncology experts to board of directors By Investing.com - Investing.com South Africa
Natera Inc Azioni (NTRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.13%
0.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):